JP2016510741A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016510741A5 JP2016510741A5 JP2015561469A JP2015561469A JP2016510741A5 JP 2016510741 A5 JP2016510741 A5 JP 2016510741A5 JP 2015561469 A JP2015561469 A JP 2015561469A JP 2015561469 A JP2015561469 A JP 2015561469A JP 2016510741 A5 JP2016510741 A5 JP 2016510741A5
- Authority
- JP
- Japan
- Prior art keywords
- solid composition
- cyclohexyl
- ylsulfanyl
- ureido
- thiazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008247 solid mixture Substances 0.000 claims description 86
- 239000004094 surface-active agent Substances 0.000 claims description 28
- HPGJSAAUJGAMLV-UHFFFAOYSA-N 2-[[2-[[cyclohexyl-(4-propoxycyclohexyl)carbamoyl]amino]-1,3-thiazol-5-yl]sulfanyl]acetic acid Chemical compound C1CC(OCCC)CCC1N(C(=O)NC=1SC(SCC(O)=O)=CN=1)C1CCCCC1 HPGJSAAUJGAMLV-UHFFFAOYSA-N 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 18
- 239000011230 binding agent Substances 0.000 claims description 17
- -1 propylene glycol fatty acid Chemical class 0.000 claims description 17
- 239000000843 powder Substances 0.000 claims description 16
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 10
- 239000000194 fatty acid Substances 0.000 claims description 10
- 229930195729 fatty acid Natural products 0.000 claims description 10
- 239000000725 suspension Substances 0.000 claims description 10
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 4
- 229940068968 polysorbate 80 Drugs 0.000 claims description 4
- 229920000053 polysorbate 80 Polymers 0.000 claims description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 4
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 150000003611 tocopherol derivatives Chemical class 0.000 claims description 3
- 229930003802 tocotrienol Natural products 0.000 claims description 3
- 239000011731 tocotrienol Substances 0.000 claims description 3
- 235000019148 tocotrienols Nutrition 0.000 claims description 3
- 238000007605 air drying Methods 0.000 claims description 2
- 239000003833 bile salt Substances 0.000 claims description 2
- 229920001400 block copolymer Polymers 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 150000005690 diesters Chemical class 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000004806 packaging method and process Methods 0.000 claims description 2
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 1
- 229930003799 tocopherol Natural products 0.000 claims 1
- 239000011732 tocopherol Substances 0.000 claims 1
- 229960001295 tocopherol Drugs 0.000 claims 1
- 235000010384 tocopherol Nutrition 0.000 claims 1
- 150000003612 tocotrienol derivatives Chemical class 0.000 claims 1
- 238000005550 wet granulation Methods 0.000 claims 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 11
- 102000030595 Glucokinase Human genes 0.000 description 7
- 108010021582 Glucokinase Proteins 0.000 description 7
- 239000012190 activator Substances 0.000 description 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 5
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical group [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 4
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000001694 spray drying Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 239000011736 potassium bicarbonate Substances 0.000 description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 125000005587 carbonate group Chemical group 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 125000005591 trimellitate group Chemical group 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361771969P | 2013-03-04 | 2013-03-04 | |
| US61/771,969 | 2013-03-04 | ||
| PCT/US2014/019363 WO2014137799A1 (en) | 2013-03-04 | 2014-02-28 | Solid compositions comprising a glucokinase activator and methods of making and using the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016510741A JP2016510741A (ja) | 2016-04-11 |
| JP2016510741A5 true JP2016510741A5 (cg-RX-API-DMAC7.html) | 2017-04-06 |
| JP6441829B2 JP6441829B2 (ja) | 2018-12-19 |
Family
ID=50288318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015561469A Active JP6441829B2 (ja) | 2013-03-04 | 2014-02-28 | グルコキナーゼ活性化剤を含む固体組成物ならびにその同じものを作製および使用する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US20160015816A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2964197B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6441829B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20150126362A (cg-RX-API-DMAC7.html) |
| CN (2) | CN112263552A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2014226292B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2903440C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2794018T3 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1213197A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL240729A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2015011110A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014137799A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2576524T1 (en) | 2010-05-26 | 2018-01-31 | Vtv Therapeutics Llc | USE OF METFORMIN IN COMBINATION WITH GLUCOIN-ACTIVE ACTIVATORS, ALSO THE COMPOSITION, COMPARING METFORMIN AND GLUCOIN-ACTIVE ACTUATOR |
| JP6234443B2 (ja) | 2012-05-17 | 2017-11-22 | ブイティーブイ・セラピューティクス・エルエルシー | 糖尿病治療のためのグルコキナーゼ活性化因子組成物 |
| RU2728824C1 (ru) * | 2016-12-15 | 2020-07-31 | Хуа Медсин (Шанхай) Лтд. | Препарат активатора глюкокиназы для перорального введения и способ его получения |
| US11541015B2 (en) | 2017-05-17 | 2023-01-03 | Massachusetts Institute Of Technology | Self-righting systems, methods, and related components |
| AU2018269711B2 (en) | 2017-05-17 | 2023-07-27 | Massachusetts Institute Of Technology | Self-righting systems and related components and methods |
| AU2019269636A1 (en) | 2018-05-17 | 2020-11-19 | Massachusetts Institute Of Technology | Systems for electrical stimulation |
| CN112040945A (zh) | 2018-06-12 | 2020-12-04 | Vtv治疗有限责任公司 | 葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途 |
| EP3917598B1 (en) | 2019-02-01 | 2025-10-29 | Massachusetts Institute of Technology | Systems for liquid injection |
| EP3819336A1 (en) * | 2019-11-08 | 2021-05-12 | Roquette Freres | Use of octenyl-succinate starches as a binder in wet granulation |
| US12391658B2 (en) | 2020-02-18 | 2025-08-19 | Vtv Therapeutics Llc | Sulfoxide and sulfone glucokinase activators and methods of use thereof |
| AU2021289309A1 (en) | 2020-06-08 | 2023-01-19 | Vtv Therapeutics Llc | Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof |
| JP2023530785A (ja) * | 2020-06-08 | 2023-07-19 | ブイティーブイ・セラピューティクス・エルエルシー | ｛２－［３－シクロヘキシル－３－（ｔｒａｎｓ－４－プロポキシ－シクロヘキシル）－ウレイド］－チアゾール－５－イルスルファニル｝－酢酸の結晶形およびその使用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1723128E (pt) * | 2004-01-06 | 2013-02-27 | Novo Nordisk As | Heteroaril-ureias e o seu uso como activadores da glicoquinase |
| CN1910166B (zh) * | 2004-01-06 | 2012-01-04 | 诺和诺德公司 | 杂芳基脲及其作为葡糖激酶活化剂的用途 |
| SI2576524T1 (en) * | 2010-05-26 | 2018-01-31 | Vtv Therapeutics Llc | USE OF METFORMIN IN COMBINATION WITH GLUCOIN-ACTIVE ACTIVATORS, ALSO THE COMPOSITION, COMPARING METFORMIN AND GLUCOIN-ACTIVE ACTUATOR |
| JP2023530785A (ja) * | 2020-06-08 | 2023-07-19 | ブイティーブイ・セラピューティクス・エルエルシー | ｛２－［３－シクロヘキシル－３－（ｔｒａｎｓ－４－プロポキシ－シクロヘキシル）－ウレイド］－チアゾール－５－イルスルファニル｝－酢酸の結晶形およびその使用 |
-
2014
- 2014-02-28 EP EP14710738.7A patent/EP2964197B1/en active Active
- 2014-02-28 CA CA2903440A patent/CA2903440C/en active Active
- 2014-02-28 KR KR1020157025034A patent/KR20150126362A/ko not_active Ceased
- 2014-02-28 ES ES14710738T patent/ES2794018T3/es active Active
- 2014-02-28 JP JP2015561469A patent/JP6441829B2/ja active Active
- 2014-02-28 KR KR1020227000773A patent/KR102694699B1/ko active Active
- 2014-02-28 AU AU2014226292A patent/AU2014226292B2/en active Active
- 2014-02-28 CN CN202011088593.3A patent/CN112263552A/zh active Pending
- 2014-02-28 HK HK16101236.4A patent/HK1213197A1/zh unknown
- 2014-02-28 MX MX2015011110A patent/MX2015011110A/es active IP Right Grant
- 2014-02-28 CN CN201480011657.6A patent/CN105188676A/zh active Pending
- 2014-02-28 WO PCT/US2014/019363 patent/WO2014137799A1/en not_active Ceased
-
2015
- 2015-08-20 IL IL240729A patent/IL240729A0/en unknown
- 2015-08-31 US US14/840,657 patent/US20160015816A1/en not_active Abandoned
-
2018
- 2018-10-16 US US16/161,581 patent/US20190046645A1/en not_active Abandoned
-
2021
- 2021-09-21 US US17/480,856 patent/US20220233701A1/en not_active Abandoned
-
2024
- 2024-12-03 US US18/967,358 patent/US20250288681A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016510741A5 (cg-RX-API-DMAC7.html) | ||
| RS62566B1 (sr) | Oralne farmaceutske kompozicije dabigatran eteksilata | |
| TW200821298A (en) | Pharmaceutical compositions | |
| RU2015128609A (ru) | Перенасыщенные стабилизированные наночастицы для слаборастворимых лекарственных средств | |
| JP2011519967A5 (cg-RX-API-DMAC7.html) | ||
| CN105188676A (zh) | 包括葡糖激酶活化剂的固体组合物及其制备和使用方法 | |
| JP5160423B2 (ja) | 水易溶性薬物含有球状素顆粒の製造方法 | |
| JP2015522653A (ja) | プロトンポンプ阻害剤の医薬組成物 | |
| CN101513403A (zh) | 含有苯并咪唑类化合物的药物制剂 | |
| WO2015145462A1 (en) | Pharmaceutical compositions of dabigatran | |
| ES2397558T3 (es) | Composición farmacéutica que comprende aleglitazar | |
| CN103381268B (zh) | 包含质子泵抑制剂的固体药物组合物 | |
| CN101347428A (zh) | 包含5-(4-(2-(n-甲基-n-(2-吡啶基)氨基)乙氧基)苄基)噻唑烷-2,4-二酮的药物组合物 | |
| TW202207930A (zh) | 包含ｈｉｆ脯胺醯基羥化酶抑制劑之調和物 | |
| JP2015086194A (ja) | ラベプラゾールナトリウム含有粒子の製造方法及びそれを含む医薬組成物 | |
| JP6361925B2 (ja) | 固形製剤 | |
| WO2018065952A1 (en) | Delayed release pharmaceutical composition of pantoprazole and process for preparation thereof | |
| CA2567400C (en) | Solid pharmaceutical formulation | |
| EP3848037B1 (en) | Solid pharmaceutical composition containing the monomethanesulfonate of a 1,3,5-triazine derivative | |
| RU2014124118A (ru) | Фармацевтические препараты, включающие аторвастатин и глимепирид | |
| JP2015514799A (ja) | サルサレートの遅延放出性医薬組成物 | |
| TR2021013983A1 (tr) | Masi̇tentan i̇çeren bi̇r kapsül formülasyonu | |
| JP2019034929A (ja) | エソメプラゾールマグネシウム水和物を含有する腸溶性コーティング製剤、およびその製造方法 | |
| WO2023038600A1 (en) | A capsule formulation comprising macitentan | |
| EP4398910A1 (en) | A capsule formulation comprising macitentan |